Evidence map›Paper›PMID 38720804›Full record

ArticleFrontiers in oncology2024

Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia.

Sonia Ahmed, Mariam Elsherif, Dina Yassin, Nahla Elsharkawy, Ayman S Mohamed, Nouran Yasser, Amr Elnashar, Hanafy Hafez, Edward A Kolb, Alaa Elhaddad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sonia Ahmed *Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Mariam Elsherif *Department of Pediatric Oncology, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt.
Dina YassinDepartment of Clinical Pathology, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt.
Nahla ElsharkawyDepartment of Clinical Pathology, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt.
Ayman S MohamedDepartment of Clinical Pathology, Children's Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt.
Nouran YasserDepartment of Research and Biostatistics, Children's Cancer Hospital (CCHE-57357), Cairo, Egypt.
Amr ElnasharDepartment of Research and Biostatistics, Children's Cancer Hospital (CCHE-57357), Cairo, Egypt.
Hanafy HafezDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Edward A KolbDepartment of Pediatric Hematology and Oncology, Nemours Center for Cancer and Blood Disorders, Wilmington, DE, United States.
Alaa ElhaddadDepartment of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Molecular testing plays a pivotal role in monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML), aiding in the refinement of risk stratification and treatment guidance. Wilms tumor gene 1 ( Methods: Quantification of Results: At diagnosis, Conclusion:

Indexed as

flow cytometrymeasurable residual diseaseoutcomepediatric AMLWT1 gene overexpression

Identifiers

PMID38720804
PMCPMC11077298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.